From Nasdaq: 2025-04-26 12:28:00

UroGen Pharma Ltd. (URGN) shared positive safety data from a Phase 1 study of UGN-301 for recurrent non-muscle invasive bladder cancer. The drug showed tolerability with no serious adverse events at all dose levels. Patients treated with UGN-301 also displayed clinical activity during the 12-week assessment. These results were presented at the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada. More health news can be found on rttnews.com.



Read more at Nasdaq: UroGen Pharma Reports Positive Phase 1 Results For UGN-301 In Non-Muscle Invasive Bladder Cancer